Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787203 | 0.85 | CA1 (0.73) | CA1CA2ERN1SRCTLR2 | |
| SCHEMBL10979734 | 0.82 | ERN1 (0.53) | CA1CA2ERN1SRCTLR2 | |
| SCHEMBL453605 | 0.82 | CA1 (0.48) | CA1CA2ERN1SRCMCL1 | |
| SCHEMBL13361454 | 0.80 | ERN1 (0.52) | CA1CA2ERN1SRCTLR2 | |
| SCHEMBL2048911 | 0.80 | NFE2L2 (0.43) | CA1CA2ERN1NFE2L2MCL1 | |
| SCHEMBL16952865 | 0.80 | NFE2L2 (0.43) | CA1CA2ERN1TLR2TLR1 | |
| SCHEMBL13332341 | 0.79 | ERN1 (0.47) | CA1CA2ERN1SRCTLR2 | |
| SCHEMBL2032770 | 0.79 | ERN1 (0.47) | CA1CA2ERN1SRCTLR2 | |
| SCHEMBL3719991 | 0.78 | NFE2L2 (0.42) | CA1CA2NFE2L2MCL1KMT2A | |
| SCHEMBL6555324 | 0.78 | ERN1 (0.55) | CA1CA2ERN1SRCTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209741-A | Preparation method of Schiff base catalyst and preparation method of polyglycolic acid | 中国科学院长春应用化学研究所 | 2023-12-12 | — | — | CN | claimed |
| CN-116867782-A | Pyrazole amide derivative | 豪夫迈·罗氏有限公司 | 2023-10-10 | — | — | CN | claimed |
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| WO-2004043903-A1 | 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| CN-1146536-C | Compounds | ʷ��˿�������ȳ�ķ����˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-1397129-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094262-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | disclosed |
| CN-1046939-C | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-12-01 | — | — | CN | disclosed |
| CN-1126468-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEM FAB (DE) | 1996-07-10 | — | — | CN | disclosed |
| CN-1094710-A | New cyclohexane derivant | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | CA1 2089/4885CA2 1314/4885ERN1 2583/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | CA1 920/4885CA2 411/4885ERN1 1279/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | CA1 2089/4885CA2 1314/4885ERN1 2583/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | CA1 361/4885CA2 1081/4885ERN1 3033/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | CA1 477/4885CA2 1235/4885ERN1 2871/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | CA1 4516/4885CA2 1322/4885ERN1 3094/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | CA1 555/4885CA2 3093/4885ERN1 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.